The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.

被引：0
|
作者：
Hoang, Tung
Sutera, Philip
Nguyen, Triet
Chang, Jin Hee
Jagtap, Shreya
Song, Yang
Shetty, Amol
Chowdhury, Dipanwita
Chan, Aaron
Carrieri, Francesca Anna
Song, Daniel Y.
DeWeese, Theodore L.
Lafargue, Audrey
Van der Eecken, Kim
Ost, Fred Bunz Piet
Tran, Phuoc T.
Deek, Matthew
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Univ Maryland, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sch Med, Baltimore, MD USA
[6] Ghent Univ Hosp, Ghent, Belgium
[7] Univ Ghent, Ghent, Belgium
[8] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17077
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.
    Ma, Xiaolong
    Zhang, Ding
    Chen, Shiqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] ignificance of distinct specifically enriched missense TP53 mutations in prostate cancer
    Vasilevskaya, Irina
    McCann, Jennifer
    McNair, Christopher
    Neupane, Neermala Poudel
    Gallagher, Peter
    Knudsen, Karen E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.
    Lu, Zhihao
    Shen, Lin
    Zhang, Henghui
    Jiao, Xi
    Wang, Yujiao
    Chen, Huan
    Han, Wenbo
    Liu, Chang
    Gong, Jifang
    Li, Jian
    Zhang, Xiaotian
    Wang, Xicheng
    Peng, Zhi
    Qi, Changsong
    Wang, Zhenghang
    Li, Yanyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?
    RoyBurman, P
    Zheng, JP
    Miller, GJ
    MOLECULAR MEDICINE TODAY, 1997, 3 (11): : 476 - 482
  • [35] Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer
    Mathiot, Laurent
    Nigen, Benoit
    Goronflot, Thomas
    Hiret, Sandrine
    Doucet, Ludovic
    Pons-Tostivint, Elvire
    Bennouna, Jaafar
    Denis, Marc G.
    Herbreteau, Guillaume
    Raimbourg, Judith
    CLINICAL LUNG CANCER, 2024, 25 (03) : 244 - 253.e2
  • [36] Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy
    Ruzzo, Annamaria
    Graziano, Francesco
    Palladino, Silvia
    Fischer, Nicholas W.
    Catalano, Vincenzo
    Giordani, Paolo
    Malkin, David
    Tamburrano, Tiziana
    Patriti, Alberto
    Petrelli, Filippo
    Sarti, Donatella
    Chiari, Rita
    ONCOLOGIST, 2024,
  • [37] Impact of germline TP53 mutations and polymorphisms in women with premenopausal breast cancer
    Samuel, Nardin
    Novokmet, Ana
    Hudson, Thomas J.
    Malkin, David
    CANCER RESEARCH, 2014, 74 (23)
  • [38] Functional genomics of TP53 mutations and its impact in breast cancer progression
    Pal, Anasuya
    Gonzalez-Malerva, Laura
    Eaton, Seron
    Guzman, Mayra
    Chow, Donald
    Yin, Hongwei
    Park, Jin
    Anderson, Karen
    LaBaer, Joshua
    CANCER RESEARCH, 2015, 75
  • [39] Prognostic Impact of TP53 Mutations and Tumor Mutational Load in Colorectal Cancer
    Ho, Vincent
    Chung, Liping
    Lim, Stephanie H.
    Ma, Yafeng
    Wang, Bin
    Lea, Vivienne
    Abubakar, Askar
    Ng, Weng
    Lee, Mark
    Roberts, Tara L.
    Chua, Wei
    Lee, C. Soon
    GASTROINTESTINAL DISORDERS, 2022, 4 (03): : 165 - 179
  • [40] The combination of immunohistochemistry for predicting TP53 mutation is useful prognostic marker in breast cancer.
    Watanabe, G.
    Ishida, T.
    Takahasi, S.
    Ishioka, C.
    Watanabe, M.
    Ohuchi, N.
    CANCER RESEARCH, 2012, 72
12345